Industrial Policy & Trade Monitor· 2663 actions· ✨ 89 recent

On June 8, 2026, the US Department of Defense published its annual update to the Section 1260H Chinese Military Companies (CMIC) list, adding 65 entities (17 new parent companies and 48 subsidiaries), bringing the total to approximately 188–200 designated entities. Major additions span EV and battery manufacturing (BYD, NIO, CATL), consumer internet (Alibaba, Baidu, Tencent), semiconductors (SMIC, YMTC, CXMT), solar (JA Solar, Trina Solar), biotech (BGI Genomics, WuXi AppTec), drones/robotics (DJI, Unitree, RoboSense), and telecoms (TP-Link). Effective June 30, 2026, DoD is prohibited from procuring goods, services, or technology directly from listed entities; effective June 30, 2027, the ban extends to indirect supply-chain procurement through prime contractors and all sub-tiers.

On 23 May 2026 President Javier Milei, Economy Minister Luis Caputo, and Chief of Staff Manuel Adorni announced the "Régimen de Incentivo para Grandes Inversiones en Nuevas Industrias" (Super RIGI), and on 26 May 2026 submitted the bill (Mensaje 181/2026, expediente 0005-PE-2026) to the Cámara de Diputados — pending Congressional approval as of filing. The regime applies a US$1 billion minimum investment threshold (with ≥20% committed in the first two years), a 15% corporate income tax rate (vs 25% under the base 2024 RIGI), accelerated depreciation of 60%/20%/20% over three years, immediate export-duty exemption (vs year 3 under RIGI), import-tariff exemption, and 30-year regulatory stability across tax, customs, social security, and FX matters. A progressive FX-liberalisation schedule allows 20% / 40% / 100% free disposal of export-generated foreign currency in years 1 / 2 / 3+. Target sectors are industries that "do not currently exist or are in experimental/pilot phase in Argentina," including semiconductors, AI data centres, advanced biotech, 100% electric vehicles, lithium value chain (downstream processing, cathode, battery), green hydrogen, solar panels, wind turbines, onshore LNG, SMR nuclear, aerospace, uranium value chain, potassium and phosphorus fertilisers, and new petrochemicals.

On 8 May 2026 China's National Health Commission released a public consultation draft proposing material amendments to the 2023 Implementation Rules for the Administrative Regulations on Human Genetic Resources, with a comment deadline of 7 June 2026. The draft narrows the statutory "foreign party" definition to a bright-line 50% equity/voting threshold (excluding VIE-structured entities), restricts "HGR Information" strictly to nucleic-acid sequence data (excluding clinical, imaging, and metabolic data), removes the separate Article 37 security-review requirement for sensitive HGR datasets, and introduces a same-day or next-working-day fast-track confirmation for international clinical trials not involving HGR information export.

The Decreto para la Autorización Inmediata de Inversiones, published in Mexico's Diario Oficial de la Federación on 4 May 2026, creates a streamlined investment-authorization mechanism under President Sheinbaum's Plan México strategy. The decree establishes an Investment Committee — composed of the Secretariats of Economía, Hacienda, SEMARNAT, SCT, Energía, and Bienestar — mandated to issue authorization certificates within 30 business days for qualifying projects, replacing the historic 6–18-month multi-agency backlog. Eligibility covers three tiers: projects in designated Polos de Desarrollo Económico para el Bienestar (Welfare Development Poles), investments of MXN 2 billion (≈USD 100M) or more, and projects in strategic sectors (semiconductors, EV batteries, critical minerals, automotive supply chain, medical devices, biotech, aerospace). This is the procedural- acceleration arm of Plan México, structurally distinct from the January 2025 Plan México tax-incentive decree (the fiscal arm), and operationalises the February 2026 Plan México expansion announced by Sheinbaum.

On 2 April 2026 President Trump issued a Presidential Proclamation under Section 232 of the Trade Expansion Act of 1962 ("Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the United States") imposing a 100% ad valorem tariff on imports of patented pharmaceutical products listed in the FDA Orange Book and Purple Book, together with the active pharmaceutical ingredients (APIs) and key starting materials used to make them. The base rate takes effect at 12:01 a.m. EDT on 31 July 2026 for the 17 manufacturers identified in Annex III, and on 29 September 2026 for all other companies. The proclamation adopts findings of the Section 232 investigation initiated by the Department of Commerce on 14 April 2025 into pharmaceuticals and APIs as a national- security supply-chain risk. The instrument is structured around a multi-tier rate ladder rather than a flat tariff: concessionary 15% rates for EU/Japan/South Korea/Switzerland/Liechtenstein under reciprocal-deal tracks, 10% for the UK with a pathway to 0% under the pending UK pharmaceutical agreement, a "+20%" surcharge for companies operating under a Commerce-approved onshoring plan (until 2 April 2030), and a 0% pathway for companies that combine an approved onshoring plan with an MFN-pricing agreement with HHS (until 20 January 2029). Generics, biosimilars and their ingredients, orphan drugs, nuclear medicines, plasma-derived therapies, fertility treatments, and cell/gene therapies are carved out.

South Korea's 13th National Strategic Technology Special Committee (chaired by MSIT) adopted the 2026 Annual Implementation Plan for the First Basic Plan for National Strategic Technology Development (2024–2028), committing KRW 8.6 trillion in 2026 R&D investment — a ~30% YoY increase from KRW 6.5 trillion in 2025 — across 19 NEXT strategic-technology fields encompassing AI, semiconductors, quantum, displays, and secondary batteries, coordinated across 23 ministries. The plan is supplemented by KRW 46.6 trillion in policy finance delivered through Korea Development Bank (KDB), Industrial Bank of Korea (IBK), Korea Credit Guarantee Fund (KCGF), and Korea Technology Finance Corporation (KOTEC), providing the horizontal funding-coordination architecture that operationalises all sector-specific Korean strategic-technology legislative instruments.

The US Department of Commerce published its final affirmative determination of sales at less-than-fair-value in the antidumping investigation of animal feed-grade L-lysine (lysine) from China (case A-570-215) on 23 July 2026, following a preliminary determination published 6 March 2026 (91 FR 11030). Commerce found a China-wide weighted-average dumping margin of 139.83% (cash deposit rate 139.65% after subsidy-offset adjustment), based on adverse facts available after Commerce found Zhengzhou Longgu Trading Co., the sole company with a calculated margin, and the Eppen Group group of producers/exporters uncooperative and ineligible for a separate rate in the final determination. A group of separate-rate companies — including Anhui BBCA Biochemical, Heilongjiang Wanlirunda Biotechnology, and others exporting through trading intermediaries such as Agromate Sg, Ainore (Tianjin), and Aollen Biotech — received a 73.55% dumping margin (73.37% cash deposit rate). The order covers lysine regardless of form (HCl, sulfate, liquid) under HTSUS 2922.41.0090 and related subheadings. A companion countervailing-duty investigation (preliminary 22 January 2026, 91 FR 2745) was finalized the same day; suspension of liquidation runs from 6 March 2026, with a final AD order contingent on an ITC injury determination due within 45 days of the final LTFV finding.

Gujarat Chief Minister Bhupendra Patel launched the Gujarat Science, Technology and Innovation (STI) Policy 2026–2031 on 1 March 2026 at the SemiConnect 2026 Conference in Gandhinagar, establishing a five-year ₹1,000 crore Swadeshi Anusandhan Fund (Indigenous Innovation Fund) for domestic R&D across strategic sectors including AI, semiconductors, quantum technologies, biotechnology, green energy, and defence. The policy targets state STI expenditure of 1% of GSDP by 2030, creation of 1 lakh skilled research professionals, 1,000+ IP filings annually, and builds three Gujarat Rajya Research and Innovation Cluster (GRRIC) corridors to anchor the state's growing semiconductor manufacturing ecosystem.

India's DGFT issued Notification No. 56/2025-26 on 29 January 2026, amending the import policy under Chapter 29 of ITC (HS) 2022 to impose minimum import prices (MIPs) on three antibiotic Active Pharmaceutical Ingredients (APIs): Penicillin G-potassium (₹2,216/kg CIF), Amoxycillin trihydrate (₹2,733/kg CIF), and 6-Aminopenicillanic Acid/6-APA (₹3,405/kg CIF). Imports below these price floors are reclassified from "Free" to "Restricted" status, requiring a DGFT import authorisation before Customs clearance. The measure takes immediate effect and is valid for approximately ten months (until 30 November 2026), with an implied renewal pathway. It is explicitly aimed at preventing very-low-priced imports and supporting domestic manufacturers built under the PLI Bulk Drugs scheme, targeting China's dominant position in global antibiotic-fermentation supply.

The US Department of Commerce published its final affirmative countervailing-duty (CVD) determination on animal feed-grade L-lysine from China (case C-570-216) on 23 July 2026, the companion subsidy proceeding to the parallel antidumping case (A-570-215) finalized the same day. Commerce found Heilongjiang Wanlirunda Biotechnology Co., Ltd. and Shouguang Golden-land Industry & Trading Co., Ltd. received countervailable subsidies at 82.11%, while Inner Mongolia Eppen Biotech Co., Ltd. and all other Chinese producers/exporters were assigned a 48.21% subsidy rate. The preliminary CVD determination, published 22 January 2026, set the initial cash-deposit rates and suspension of liquidation; the final determination confirmed and aligned the case with the AD final determination for a joint ITC injury vote.

The British Business Bank, the UK government's state-owned economic development bank, announced a GBP 50 million cornerstone commitment to Epidarex Capital's new life sciences fund on 20 January 2026. The fund, Epidarex Capital IV, LP, went on to announce a first close of USD 145 million on 27 January 2026, with the Bank joined by the Strathclyde Pension Fund, the Scottish National Investment Bank, and other family-office and corporate investors. This is the Bank's second cornerstone commitment to an Epidarex fund, following a GBP 50 million stake in Epidarex Capital III UK, LP in 2020.